Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

The Pentagon has temporarily rescinded a recently published guidance that would require all military personnel aged 30 and over to receive testosterone level testing to check for deficiencies.

September 11, 2026

Vol.52 No.33

By Claire Marie Porter

In Brief

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Lawrence Fong was appointed senior vice president and director of Fred Hutch’s Translational Science and Therapeutics Division, effective Dec. 1.

September 11, 2026

Vol.52 No.33

In Brief

Fred Hutch researchers receive multi-year funding from the V Foundation

Two Fred Hutch Cancer Center researchers have recently been awarded multi-year research grants from the V Foundation for Cancer Research.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

Drugs & Targets

FDA approves Pluvicto for mHSPC

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

August 07, 2026

Vol.52 No.31

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

YOU MAY BE INTERESTED IN

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Fred Hutch researchers receive multi-year funding from the V Foundation

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

FDA approves Pluvicto for mHSPC

Renew today!

Subscriber content

Never miss an issue!

Login